ID   ACN
AC   CVCL_1068
DR   CLO; CLO_0001655
DR   CLDB; cl239
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1068
DR   Cell_Model_Passport; SIDM00057
DR   ChEMBL-Cells; CHEMBL3308148
DR   ChEMBL-Targets; CHEMBL2366195
DR   Cosmic; 906803
DR   Cosmic-CLP; 906803
DR   DepMap; ACH-002389
DR   EGA; EGAS00001000978
DR   GDSC; 906803
DR   GEO; GSM1669594
DR   IARC_TP53; 21170
DR   ICLC; HTL96020
DR   LINCS_LDP; LCL-1982
DR   PharmacoDB; ACN_55_2019
DR   PubChem_Cell_line; CVCL_1068
DR   Wikidata; Q54608539
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=1354203;
RX   PubMed=2467885;
RX   PubMed=8509230;
RX   PubMed=15150552;
RX   PubMed=20164919;
RX   PubMed=30894373;
CC   Problematic cell line: Probably contaminated. The STR profile of ACN and LN-464 are identical. SNP analysis (DepMap) also shows identity of both cell lines. We believe this is a melanoma cell line based on the presence of the BRAF V600E mutation as well as the RNASeq expression profile of LN-464 (DepMap) which clusters with that of melanoma patient samples. Originally thought to originate from the bone marrow of a 36-month old boy with a metastatic adrenal stage-IV neuroblastoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.3%; Native American=0.69%; East Asian, North=0%; East Asian, South=0.16%; South Asian=1.02%; European, North=70.67%; European, South=27.16% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; ICLC
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,13
ST   D16S539: 11
ST   D18S51: 16
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 10,13
ST   D8S1179: 12,13
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 10,14
ST   TH01: 9
ST   TPOX: 9,12
ST   vWA: 14,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_3962 ! LN-464
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=1354203; DOI=10.1002/ijc.2910520116;
RA   Gross N., Favre S., Beck D., Meyer M.;
RT   "Differentiation-related expression of adhesion molecules and
RT   receptors on human neuroblastoma tissues, cell lines and variants.";
RL   Int. J. Cancer 52:85-91(1992).
//
RX   PubMed=2467885; DOI=10.1002/ijc.2910430421;
RA   Gross N., Beck D., Portoukalian J., Favre S., Carrel S.;
RT   "New anti-GD2 monoclonal antibodies produced from
RT   gamma-interferon-treated neuroblastoma cells.";
RL   Int. J. Cancer 43:665-671(1989).
//
RX   PubMed=8509230; DOI=10.1002/ijc.2910540329;
RA   Rimoldi D., Romero P., Carrel S.;
RT   "The human melanoma antigen-encoding gene, MAGE-1, is expressed by
RT   other tumour cells of neuroectodermal origin such as glioblastomas and
RT   neuroblastomas.";
RL   Int. J. Cancer 54:527-528(1993).
//
RX   PubMed=15150552; DOI=10.1038/sj.bjc.6601842;
RA   Airoldi I., Meazza R., Croce M., Di Carlo E., Piazza T., Cocco C.,
RA   D'Antuono T., Pistoia V., Ferrini S., Corrias M.V.;
RT   "Low-dose interferon-gamma-producing human neuroblastoma cells show
RT   reduced proliferation and delayed tumorigenicity.";
RL   Br. J. Cancer 90:2210-2218(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//